Cytokinetics, Incorporated
CYTK
$60.06
$0.060.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.00% | -90.71% | 6.24% | -18.97% | -9.59% |
| Total Depreciation and Amortization | 20.06% | 11.12% | -5.03% | -1.33% | -62.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.45% | 271.04% | 72.66% | 10.70% | 246.53% |
| Change in Net Operating Assets | -104.42% | 127.95% | -623.30% | 79.76% | -7.05% |
| Cash from Operations | -117.56% | -5.92% | -29.12% | -1.63% | 11.44% |
| Capital Expenditure | -337.52% | -1,234.38% | -116.45% | -- | -1,575.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -158.45% | -38.95% | 108.78% | 241.96% | 237.89% |
| Cash from Investing | -164.22% | -57.55% | 108.12% | 224.61% | 236.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 6.59% | -13,901.69% | 6.25% | -209.44% | -1,212.61% |
| Issuance of Common Stock | 126.05% | 9.75% | -98.92% | -93.79% | -96.17% |
| Repurchase of Common Stock | -3.30% | -- | -- | 99.93% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -62.50% | -- | -- |
| Cash from Financing | 4,543.67% | 9,548.64% | -90.43% | -95.42% | -98.59% |
| Foreign Exchange rate Adjustments | -34.59% | 136.51% | -4,362.50% | -1,100.00% | 1,560.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -314.61% | 206.12% | -96.44% | -404.62% | 259.80% |